title: GABAB receptor-mediated mechanisms in the RVLM studied by microinjections of two GABAB receptor antagonists.
abstract: The cardiovascular effects of microinjections of two gamma-aminobutyric acid (GABA) antagonists specifically acting on GABAB receptors, 2-hydroxy-saclofen (2-OH-S) and CGP-35348, into vasopressor sites of rostral ventrolateral medulla (RVLM) were studied in rats anesthetized with urethan. Bilateral microinjection of 2-OH-S induced significant increases in mean arterial pressure (MAP) and heart rate (HR) in 21 of 26 RVLM vasopressor sites (81%); average increases obtained in the 26 sites studied were +25.2 +/- 3.0 mmHg and +12.7 +/- 2.1 beats/min. Bilateral microinjection of CGP-35348 induced significant increases in MAP and HR in 10 of 12 RVLM sites (83%). Average increases in the 12 sites studied were +27.6 +/- 3.9 mmHg and +14.6 +/- 2.5 beats/min. Sixteen rats received unilateral electrolytic lesions of one RVLM. Microinjections of either 2-OH-S or CGP-35348 into vasopressor sites within the intact RVLM significantly antagonized the depressor responses observed after injections of baclofen (20 pmol) into the same sites, whereas both GABAB antagonists did not affect the depressor response induced by microinjection of muscimol (5 pmol). These results suggest a tonic inhibitory mechanism within the RVLM mediated by GABAB receptors involved in central cardiovascular regulation.
authors.affiliation: Istituto di Fisiologia Umana, Università degli Studi, Genoa, Italy.
authors.forename: G L
authors.initials: GL
authors.lastname: Avanzino
authors.forename: P
authors.initials: P
authors.lastname: Ruggeri
authors.forename: D
authors.initials: D
authors.lastname: Blanchi
authors.forename: C E
authors.initials: CE
authors.lastname: Cogo
authors.forename: R
authors.initials: R
authors.lastname: Ermirio
authors.forename: L C
authors.initials: LC
authors.lastname: Weaver
mesh_terms: D000818:Animals; D001418:Baclofen / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects* / Q000502:physiology; D004562:Electrocardiography / Q000187:drug effects; D007839:Functional Laterality; D058788:GABA-B Receptor Antagonists; D006339:Heart Rate / Q000187:drug effects* / Q000502:physiology; D006706:Homeostasis; D008297:Male; D008526:Medulla Oblongata / Q000187:drug effects / Q000502:physiology*; D008845:Microinjections; D009118:Muscimol / Q000008:administration & dosage / Q000494:pharmacology; D009943:Organophosphorus Compounds / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D018080:Receptors, GABA-B / Q000502:physiology*
chemical_list: D058788:GABA-B Receptor Antagonists; D009943:Organophosphorus Compounds; D018080:Receptors, GABA-B; D009118:Muscimol; C066430:CGP 35348; D001418:Baclofen; C057491:2-hydroxysaclofen